Cooper Companies (NASDAQ:COO) Sets New 52-Week Low After Analyst Downgrade

The Cooper Companies, Inc. (NASDAQ:COO)’s stock price reached a new 52-week low during trading on Thursday after Needham & Company LLC lowered their price target on the stock from $86.00 to $73.00. Needham & Company LLC currently has a buy rating on the stock. Cooper Companies traded as low as $52.49 and last traded at $51.9960, with a volume of 249326 shares traded. The stock had previously closed at $63.48.

COO has been the subject of a number of other reports. Robert W. Baird set a $61.00 price objective on shares of Cooper Companies and gave the stock a “neutral” rating in a report on Thursday. Piper Sandler downgraded Cooper Companies from an “overweight” rating to a “neutral” rating and set a $59.00 price objective for the company. in a report on Thursday. Wells Fargo & Company restated a “sell” rating and set a $66.00 target price (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. Bank of America reiterated a “neutral” rating and set a $65.00 target price (down from $80.00) on shares of Cooper Companies in a report on Thursday. Finally, Mizuho set a $85.00 price target on shares of Cooper Companies and gave the company an “outperform” rating in a report on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $74.93.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
• Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
• Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
• Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.

Institutional Trading of Cooper Companies

Several institutional investors and hedge funds have recently made changes to their positions in COO. Algert Global LLC bought a new stake in shares of Cooper Companies in the 2nd quarter worth $7,655,000. BlackRock Inc. acquired a new stake in shares of Cooper Companies during the 2nd quarter worth $1,077,762,000. Heartland Advisors Inc. purchased a new stake in shares of Cooper Companies during the fourth quarter valued at approximately $15,348,000. Tocqueville Asset Management L.P. acquired a new stake in Cooper Companies during the second quarter valued at approximately $1,502,000. Finally, Western Standard LLC acquired a new position in Cooper Companies during the 2nd quarter valued at about $5,228,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Price Performance

The company has a market cap of $10.23 billion, a price-to-earnings ratio of 44.42, a PEG ratio of 1.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The company’s 50 day moving average price is $72.42 and its 200-day moving average price is $70.02.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the business posted $0.49 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities research analysts forecast that The Cooper Companies, Inc. will post 4.63 earnings per share for the current fiscal year.

Cooper Companies declared that its board has initiated a share buyback program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.